The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Still small shareholders Holders of Record As of March 9, 2018, there were 424 holders of record of our common stock.
Highlights - thought this was dead SynBio applied for and received regulatory approval to commence ErepoXen Phase II(b)/III human clinical trials in Russia and is currently recruiting patients. SynBio has indicated that it intends to commence the commercialization and marketing stages of ErepoXen in the Russian and CIS markets subject to approval in such markets.
Well, they must still have faith in PolyXen, despite the Shire failure last year. But how many more years before they manage to squeeze blood from the stone is anyone's guess.
4:55 PolyXen: A Polysialylation Technology for Enhancing Therapeutic Proteins and Their Clinical Applications Curtis Lockshin, PhD, Chief Scientific Officer, Xenetic Biosciences, Inc. PolyXen™ is a proprietary platform for conjugating polysialic acid (PSA) to protein or peptide therapeutics, which can improve their pharmacological properties. Preclinical and human clinical data has been generated with a number of compounds, including recombinant Factor VIII, rhEPO, and oxyntomodulin. Therapeutic proteins polysialylated with the PolyXen platform have displayed extended circulating half-life, improved thermodynamic stability and protease resistance, while retaining pharmacological activity. We have seen no evidence to date of PSA- induced immunogenicity, an issue commonly associated with PEG.
I was wrong
https://d1io3yog0oux5.cloudfront.net/_328648ecd9e6b2116e7b1186279bb754/xeneticbio/db/213/1176/pdf/Xenetic_Presentation_February+2018.pdf New IR people too
No news, yet the share price did its periodic spike again last week. I've reduced a lot here, painful but us PIs have no way of telling what's going on any more, and as you say, Clem, there's only 101 left in the bag. Of course it could turn around in a flash on good trial news, but XBIO's track record does not inspire confidence, nor does its IR.
is the only thing on the pipeline page now what happened to everything else. Clem
The Baxalta (now part of Shire) study results for PolyXen were submitted to clinicaltrials.gov on January 14, 2018 but are not yet publicly available. The study completion date was January 17 2017. The estimated primary completion date for XBIO -101 (Virexxa) was January 2018 and the estimated study completion date is July 2018. No results have been posted but Kevelt the study sponsor, and Pharmsyntez has this information so XBIO should have it too. However, the Virexxa drug will be manufactured in Estonia, but no mention of XBIO getting a slice of the action. In 2015 Kevelt sold the rights of Virexxa to US stock company Xenetic Biosciences Inc. (see: http://www.jforcs.com/wp-content/uploads/2016/08/Therapeutics-2-Virexxa.pdf ). Virexxa has orphan drug status in the US and that was in 2016. Is the company still waiting for the study 2 resuts? The product pipeline is reduced and I'm surprised that the company is still afloat, considering that there is no news at all.
9,182 from corp presentation in DEC Insiders own 8,697 of all potential shares thats 94.7% so much for bloody liquidity....
Looks like the same old XBIO - down 12% again.
come on $9..... thats what I worked out it needs to be to equal the old 6p AIM price...
to get some money back.
Life in the old dog?
My theory is there is no new collaboration with Baxter - it was a payoff. Made to look like this instead of saying your product is useless. Otherwise where is it? So down to one now...... Where is the other products gone.......... All smoke and mirrors..... One positive is they been giving that XBIO-101 to millions safely for years in Russia and seem to have results from the presentation below in Estonia
Come on, surely Xenetic can get into the Blockchain and Crypto space, at least change its name to froth up the share price.... Xenetic Cryptosciences anyone? :)
Two Irishmen were driving home one night when one asked the other to check if the car's indicators are working. He promptly sticks his head out the window and says: "Yes, no, yes, no, yes, no, yes, no."
This year rodders..... this year.
As the Christmas spirit will be flowing over the festivities I would like to share an experience with you all, about drinking and driving. As you well know, some of us have been known to have had brushes with the authorities on our way home from the odd social session over the years. A couple of nights ago, I was out for a few drinks with some friends and had a few too many beers and some rather nice claret. Knowing full well I may have been slightly over the limit, I did something I've never done before - I took a bus home. I arrived home safely and without incident, which was a real surprise, as I have never driven a bus before and am not sure where I got this one.
thats two giveaways on the last working day before christmas. This time its the biggest ever
You forgot to mention the raging successes that seem to have disappeared into the toxic waste bin - EPO, OncoHist etc.
That's meant for Leeson BY THE WAY
If you have nothing intellectual to post please drink untill the urge to post passes.